Key Takeaways
- A first launch requires the company itself to become commercially capable—not only promotional readiness.
- If departments describe the patient journey differently, commercial alignment is incomplete.
- Coverage should not be confused with access; organization and governance determine whether plans can execute.
- Readiness is about identifying the greatest risks while leadership still has time to act.
A first product launch represents a fundamental transformation for an emerging biotechnology company.
Success requires far more than preparing promotional materials and recruiting a sales team. The company itself must become commercially capable.
Leadership should evaluate readiness across eight areas. For a structured engagement, see PharmaKonsult’s biotech launch readiness assessment.
1. Market Understanding
Can the organization clearly explain who the patient is, how the patient is diagnosed, where diagnosis is delayed, who treats the patient, how referral occurs, where treatment decisions are made and which institutions influence care?
If different departments give materially different answers, commercial alignment is incomplete.
2. Commercial Opportunity
Pressure-test the forecast. Ask how much of prevalence is actually diagnosed, how many diagnosed patients are eligible, how many are realistically reachable, how quickly adoption could occur and which assumptions have never been independently challenged.
Forecast precision does not compensate for weak assumptions.
3. Competitive Understanding
Leadership should understand not only products currently available but how the market may look at launch—clinical-stage competitors, expected labels, physician habits, switching barriers, treatment guidelines and emerging modalities.
The launch is occurring in a future market, not today’s market.
4. Evidence
Clinical efficacy is critical. Commercial adoption may nevertheless depend upon additional evidence: physician education, health economics, quality of life, patient journey, resource utilization, real-world evidence and differentiation.
Identify evidence gaps while there is still time to address them.
5. Market Access
Ask whether the organization understands the payer landscape, reimbursement barriers, prior authorization, distribution, specialty pharmacy, patient support and affordability.
Coverage alone should not be confused with access. See also commercial market access strategy.
6. Organization
Determine which capabilities must be internal, what should be outsourced, who owns each capability, hiring sequence, leadership requirements, budget and dependencies.
The organization should be designed around the market. Guidance on that design is covered in commercial organization strategy.
7. Cross-Functional Governance
Commercialization requires coordination across functions. Leadership needs clarity around decision rights, milestones, accountability, escalation, risk and launch governance.
Without governance, even strong functional plans can become disconnected.
8. Execution
Finally ask: Can the organization execute? A strategy should ultimately translate into actions, owners, deadlines, metrics, dependencies and decisions.
Launch readiness exists when these elements operate as a coherent system.
The Most Important Question
The purpose of a readiness assessment is not to achieve perfect preparation. No launch will ever contain complete certainty.
The purpose is to identify the assumptions and capabilities that create the greatest risk while leadership still has the opportunity to act—especially ahead of a first commercial launch.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
